45 clinical trials
grid
list
download
| Body (indexed field) | Identifiant (ID) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 22655 | Any line | Ahmad Hussein Awada | Solid tumors | Incyte Corporate | INCB59872-101 | Trial closed | A Phase 1/2, Open-Label, Dose-Escalation / Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced Malignancies | ahmad.awada@hubruxelles.be | 1/2 | 1 | |
| 22849 | Be a parent or close relative of a child between the ages of 3 and 18 confronted with parental cancer, any tumors | Solid tumors | Intervention destinée aux parents | Trial open for recruitment | L'enfant face au cancer d'un parent: une étude randomisée évaluant l'efficacité d'une intervention psychologique destinée à soutenir la parentalité | ||||||
| 29236 | Bogdan Grigoriu | Lung | AbbVie | LUMINOSITY | Trial closed for recruitment | Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer | Bogdan.Grigoriu@hubruxelles.be | 2 | 2 | ||
| 22664 | Stage IV NSCLC. Progression Under or after platinium regimen | Thierry Berghmans | Multiple | Novocure Gmbh | LUNAR | Trial closed | LUNAR: Pivotal, randomized, open-label study of Tumor Treating Fields(TTFields) concurrent with standard of care therapies for treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure (avis 09/04/19) | 3 | 3 | ||
| 29765 | Bogdan Grigoriu | Lung | AbbVie | M18-868 | Trial open for recruitment | A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (M18-868) | Bogdan.Grigoriu@hubruxelles.be | 3 | 3 | ||
| 29447 | Mariana Brandao | Multiple | Merus | MCLA-129-CL01 | Trial open for recruitment | Phase 1/2 dose escalation and expansion study evaluating MCLA-129, a human anti-EGFR and anti-c-MET bispecific antibody, in patients with advanced NSCLC and other solid tumors | mariana.brandao@hubruxelles.be | 1/2 | 1 | ||
| 29751 | Mariana Brandao | Lung | Merck | MS201924-0022 | Trial open for recruitment | An open-label, multicenter, phase 1b/2a study to evaluate efficacy, safety, tolerability, and pharmacokinetics of the ATR inhibitor M1774 in combination wit cemiplimab in participants with non-squamous non-small cell lung cancer that has progressed on prior anti-PD-(L)1 and platinum-based therapies | mariana.brandao@hubruxelles.be | 1b | 1 | ||
| 22668 | second line metastatic | Thierry Berghmans | Thymus | EORTC | Nivothym | Trial closed for recruitment | Single-arm, multicenter, phase II study of nivolumab in patients with type B3 thymoma and thymic carcinoma previously treated with chemotherapy - (Nivothym) | 2 | 2 | ||
| 22675 | Any line/RECIST v1.1/Eligible for platinium salt chemotherapy | Nuria Kotecki | Multiple | Onxeo | OX2016-203-01 | Trial closed | An open-label, dose-escalation, phase I study to assess the safety, pharmacokinetics and pharmacodynamics of AsiDNA, a DNA repair inhibitor administered intravenously in patients with advanced solid tumors | Nuria.Kotecki@hubruxelles.be | 1 | 1 | |
| 22727 | Advanced, recurrent, ou unresecable | Ahmad Hussein Awada | Lung | AstraZeneca | PACIFIC R | Trial closed for recruitment | First real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy - PACIFIC Real World, PACIFIC-R | ahmad.awada@hubruxelles.be | 4 | 4 | |
| 22762 | Adjuvant. ECOG 0 or 1 | Thierry Berghmans | NSCLC | Merck | PEARLS | Trial closed for recruitment | A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS) | 3 | 3 | ||
| 22623 | brca 1/2 | Ahmad Hussein Awada | Multiple | PharmaMar | PM1183-B-005-14 | Trial closed | A Multicenter Phase II Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors | ahmad.awada@hubruxelles.be | 2 | 2 | |
| 22819 | Available tumor tissue | Martine Piccart | Multiple | Institut Jules Bordet | PRECISION | Trial closed | The Jules Bordet Institute Program for Molecular Profiling of Metastatic Lesions : Feasibility | martine.piccart@hubruxelles.be | |||
| 29756 | Mariana Brandao | Lung | AstraZeneca | SAFFRON | Trial open for recruitment | A phase III, randomised, Open-Label study of Savolitinib in combination with Osimertinib versus platinium-based doublet chemotherapy in participants with EGFR mutated MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who have progressed on treatment with Osimertinib | mariana.brandao@hubruxelles.be | 3 | 3 |